Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,

Slides:

Advertisements

Similar presentations

Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.

Advertisements

LaCasce A et al. Proc ASH 2014;Abstract 293.

Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.

DLBCL with less than PR to second line therapy… Correcting a Misconception…. Koen van Besien, MD Weill Cornell Medical College, NY.

What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.

Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment.

Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.

Vose JM et al. Proc ASH 2011;Abstract 661.

Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide Asha Johny, Kevin W.

Reeder CB et al. ASCO 2009; Abstract (Poster)

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions Chelsea.

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Goede V et al. Proc ASH 2014;Abstract 3327.

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Erba HP et al. Blood 2008;112: Abstract 558

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

by James O. Armitage, and Dan L. Longo

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Nonmyeloablative conditioning for relapsed follicular lymphoma

R-CHOP Stem Cell Transplantation for Follicular Lymphoma

Short-pulse B–non-Hodgkin lymphoma–type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias by David Gómez-Almaguer, Manuel Solano-Genesta,

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

by J. Rodriguez, M. A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

by Michael F. Leahy, and J. Harvey Turner

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,

What is the optimal management of a 43-year-old man with high-risk FL not in CR after R-chemo? Answer: Radioimmunotherapy Peter Martin, M.D. The Charles,

Stephen Ansell, MD, PhD Mayo Clinic

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,

Grövdal M et al. Blood 2008;112:Abstract 223.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma by Paul M. Barr, Thomas P. Miller, Jonathan W. Friedberg,

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review Denise M.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Advani RH et al. Proc ASH 2011;Abstract 443.

Supplementary Figure 2A

Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study Luis F.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma.

CR-rate ratios with 95% CIs

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia by Nicola Gökbuget, Hervé Dombret, Massimiliano.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

by Richard L. Piekarz, Robin Frye, H. Miles Prince, Mark H

by Jan J. Cornelissen, and Didier Blaise

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Genomic determinants of response to cytotoxic chemotherapy.

by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

Optimizing therapy for nodal marginal zone lymphoma

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis by.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Presentation transcript:

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman, Maria Alma Rodriguez, Michael Fennessy, Thomas C. Shea, Gary Spitzer, Izidore S. Lossos, Mohamed A. Kharfan-Dabaja, Robin Joyce, Luis Fayad, Kristen Henkel, Qiming Liao, Klaus Edvardsen, Roxanne C. Jewell, Doug Fecteau, Rajendra P. Singh, Steen Lisby, and Craig H. Moskowitz Blood Volume 122(4):499-506 July 25, 2013 ©2013 by American Society of Hematology

Treatment protocol. Treatment protocol. Routine cycle length was 21 days. *Stem cell mobilization could be performed in cycle 2 and/or cycle 3. FL, follicular lymphoma; Gr3B, grade 3B; O, ofatumumab; PD, progressive disease. Matthew J. Matasar et al. Blood 2013;122:499-506 ©2013 by American Society of Hematology

CONSORT diagram of distribution of patients according to treatment assignation. CONSORT diagram of distribution of patients according to treatment assignation. O, ofatumumab. Matthew J. Matasar et al. Blood 2013;122:499-506 ©2013 by American Society of Hematology

Progression free survival. Progression free survival. (A) PFS for O-DHAP and O-ICE. Median PFS for O-DHAP was 301 days (95% confidence interval [CI] 152, not estimable); median PFS for O-ICE was 288 days (95% CI 177, not estimable). (B) PFS according to saaIPI, 0 to 1 risk factors vs 2 to 3 risk factors. Median PFS for 0 to 1 risk factors was not reached (95% CI: 288, not estimable), median PFS for 2 to 3 risk factors was 177 days (95% CI 117, 264). (C) PFS according to response to first-line therapy, CR >12 months vs CR ≤ 12 months or failure to achieve remission. Median PFS for CR >12 months was not reached (95% CI 375, not estimable); median PFS for CR ≤ 12 months or failure to achieve remission was 261 days (95% CI 152, 296). O, ofatumumab. Matthew J. Matasar et al. Blood 2013;122:499-506 ©2013 by American Society of Hematology